{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gpt-5.1",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Run-in Period Duration",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Study Start",
        "windowLower": -7,
        "windowUpper": -5
      },
      {
        "id": "timing_2",
        "name": "Pretreatment Copper/Molybdenum Baseline Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Study Start",
        "windowLower": -4,
        "windowUpper": -1
      },
      {
        "id": "timing_3",
        "name": "Initial 15 mg/day Treatment Duration Before Titration",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 28
      },
      {
        "id": "timing_4",
        "name": "Titration to 30 mg/day",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowLower": 29,
        "windowUpper": 29
      },
      {
        "id": "timing_5",
        "name": "Safety Review for Dose Titration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 23,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 23
      },
      {
        "id": "timing_6",
        "name": "Intake/Output Collection Baseline Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Study Start",
        "windowLower": -4,
        "windowUpper": -1
      },
      {
        "id": "timing_7",
        "name": "Intake/Output Collection for 15 mg Initial Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 8
      },
      {
        "id": "timing_8",
        "name": "Intake/Output Collection Mixed 15 mg/30 mg Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 15,
        "relativeTo": "First Dose",
        "windowLower": 25,
        "windowUpper": 39
      },
      {
        "id": "timing_9",
        "name": "Accumulation Period to Steady State",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 10
      },
      {
        "id": "timing_10",
        "name": "Possible Discharge from CRU After Inpatient Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 9,
        "relativeTo": "First Dose",
        "windowLower": 9,
        "windowUpper": 9
      },
      {
        "id": "timing_11",
        "name": "Readmission for Inpatient Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose",
        "windowLower": 22,
        "windowUpper": 23
      },
      {
        "id": "timing_12",
        "name": "Outpatient Period Maximum Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 14
      },
      {
        "id": "timing_13",
        "name": "Inpatient Period 1 Duration",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 18,
        "relativeTo": "Study Start",
        "windowLower": -8,
        "windowUpper": 9
      },
      {
        "id": "timing_14",
        "name": "Inpatient Period 2 Duration",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 18,
        "relativeTo": "First Dose",
        "windowLower": 23,
        "windowUpper": 40
      },
      {
        "id": "timing_15",
        "name": "EOS Visit Window After Day 40",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "End of Treatment",
        "windowLower": 12,
        "windowUpper": 16
      },
      {
        "id": "timing_16",
        "name": "EOS Visit Nominal Timing",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": 52,
        "windowUpper": 56
      },
      {
        "id": "timing_17",
        "name": "End of Study Blood Sampling Days",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 1
      },
      {
        "id": "timing_18",
        "name": "PK/PD 24-hour Collections",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 0,
        "relativeTo": "First Dose",
        "windowLower": 1,
        "windowUpper": 39
      },
      {
        "id": "timing_19",
        "name": "Predose PK/PD Sampling Days",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 0,
        "relativeTo": "First Dose",
        "windowLower": 4,
        "windowUpper": 38
      },
      {
        "id": "timing_20",
        "name": "Fasting Before Study Intervention in CRU",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "First Dose",
        "windowLower": -10,
        "windowUpper": 0
      },
      {
        "id": "timing_21",
        "name": "Allowed Deviation from Usual Dosing Time as Outpatient",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "Previous Visit",
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_22",
        "name": "Meal Delay After ALXN1840 Dose",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose",
        "windowLower": 2,
        "windowUpper": 24
      },
      {
        "id": "timing_23",
        "name": "Serum Chemistry Fasting Requirement at Screening and Check-in",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "Screening",
        "windowLower": -8,
        "windowUpper": 0
      },
      {
        "id": "timing_24",
        "name": "Allowed Shorter Fast for Rechecks/Postdose Serum Chemistry",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Previous Visit",
        "windowLower": -6,
        "windowUpper": 0
      },
      {
        "id": "timing_25",
        "name": "Laboratory Assessments Core Days",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 0,
        "relativeTo": "First Dose",
        "windowLower": -8,
        "windowUpper": 28
      },
      {
        "id": "timing_26",
        "name": "Home or Site Urine Pregnancy Testing Frequency",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 28
      },
      {
        "id": "timing_27",
        "name": "24-hour Urine Collection Periods",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 1
      },
      {
        "id": "timing_28",
        "name": "Encouraged Voiding at End of 24-hour Period",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 2
      },
      {
        "id": "timing_29",
        "name": "Chelator Discontinuation Before ALXN1840 Initiation",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose",
        "windowLower": -4,
        "windowUpper": -1
      },
      {
        "id": "timing_30",
        "name": "Zinc Discontinuation Prior to Day 1",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose",
        "windowLower": -21,
        "windowUpper": -1
      },
      {
        "id": "timing_31",
        "name": "Prior Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening",
        "windowLower": -90,
        "windowUpper": -1
      },
      {
        "id": "timing_32",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "Screening",
        "windowLower": -14,
        "windowUpper": -1
      },
      {
        "id": "timing_33",
        "name": "Nonprescription Medication/Supplement Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "Screening",
        "windowLower": -7,
        "windowUpper": -1
      },
      {
        "id": "timing_34",
        "name": "Maximum Cannula Dwell Time",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 72,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 72
      },
      {
        "id": "timing_35",
        "name": "Cannula Flush Frequency",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 8
      },
      {
        "id": "timing_36",
        "name": "Maximum Number of Rechallenges",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 3
      },
      {
        "id": "timing_37",
        "name": "Notification to Alexion for Clinically Concerning Abnormalities",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 24,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 24
      },
      {
        "id": "timing_38",
        "name": "Alcohol Abstinence Before Study Intervention Administration",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose",
        "windowLower": -48,
        "windowUpper": 0
      },
      {
        "id": "timing_39",
        "name": "Minimum Collection Period Length",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Previous Visit",
        "windowLower": 3,
        "windowUpper": 3
      },
      {
        "id": "timing_40",
        "name": "Maximum Collection Period Length",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 15,
        "relativeTo": "Previous Visit",
        "windowLower": 15,
        "windowUpper": 15
      },
      {
        "id": "timing_41",
        "name": "Bowel Transit Time Consideration",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 40,
        "relativeTo": "Previous Visit",
        "windowLower": 33,
        "windowUpper": 47
      },
      {
        "id": "timing_42",
        "name": "Weekly Repeat Testing for Safety Laboratory Parameters",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "Previous Visit",
        "windowLower": 7,
        "windowUpper": 7
      },
      {
        "id": "timing_43",
        "name": "Actions Prior to Declaring Lost to Follow-up",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 3
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Safety Review for Dose Increase to 30 mg",
        "instanceType": "Condition",
        "description": "Safety Review Committee evaluation prior to increasing dose from 15 mg/day to 30 mg/day",
        "text": "Before titration to 30 mg/day on Day 29, the Safety Review Committee will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Continuation on 15 mg/day Instead of Titration",
        "instanceType": "Condition",
        "description": "Remain on 15 mg/day if safety concerns exist after approximately 4 weeks",
        "text": "Dosing for ALXN1840 will be initiated at 15 mg once daily for a minimum of 4 weeks, with an increase to 30 mg after 4 weeks, unless there are safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk, in which case, participants may remain on the 15 mg/day dose for the duration of the study."
      },
      {
        "id": "cond_3",
        "name": "Dose Modification Criteria General Rule",
        "instanceType": "Condition",
        "description": "Global rule to decrease or interrupt dose when predefined laboratory or clinical criteria are met",
        "text": "The dose should be decreased or interrupted if any of the relevant Dose Modification Criteria are met. Deviation from the dose modification guidelines must be agreed with the Alexion Medical Monitor."
      },
      {
        "id": "cond_4",
        "name": "Hematologic Dose Reduction Criteria (Example)",
        "instanceType": "Condition",
        "description": "Criteria based on neutrophil decrease triggering dose reduction and restriction of increase",
        "text": ">30% decrease from baseline in participants with neutrophils below reference range at baseline: reduce dose to previous dose level if up-titration has occurred or reduce dose to 15 mg every other day if on 15 mg once daily. No further dose increase until resolution of abnormality."
      },
      {
        "id": "cond_5",
        "name": "Liver Injury Dose Interruption Criteria",
        "instanceType": "Condition",
        "description": "Bilirubin and ALT criteria requiring temporary interruption and specific conditions for rechallenge",
        "text": "If bilirubin > 2 × ULN accompanied by ALT > 3 × ULN, indicative of liver injury: temporarily interrupt ALXN1840; perform weekly repeat testing; rechallenge only at 15 mg every other day or less frequent when bilirubin is below ULN and with approval of the Alexion Medical Monitor. A maximum of 3 rechallenges will be allowed."
      },
      {
        "id": "cond_6",
        "name": "Neurologic Worsening Management",
        "instanceType": "Condition",
        "description": "Criteria and process for dose modification in case of neurological worsening",
        "text": "Evidence of neurologic worsening by adverse events or by neurologic physical exam assessment will prompt the Investigator and Alexion Medical Monitor to evaluate the need for dose interruption, increase, or decrease based on copper control parameters and relevant clinical data; rationale must be documented and re-evaluated at the next study visit."
      },
      {
        "id": "cond_7",
        "name": "Psychiatric Worsening Management",
        "instanceType": "Condition",
        "description": "Criteria and process for dose modification in case of clinically significant psychiatric worsening",
        "text": "Evidence of clinically significant acute psychiatric worsening (including but not limited to suicidality, acute depression, or psychosis) will prompt the Investigator and Alexion Medical Monitor to evaluate the need for dose interruption, increase, or decrease based on copper control parameters and relevant clinical data; rationale must be documented and re-evaluated at the next study visit."
      },
      {
        "id": "cond_8",
        "name": "Eligibility – Zinc Washout",
        "instanceType": "Condition",
        "description": "Minimum zinc-free period prior to starting ALXN1840 to avoid confounding copper balance",
        "text": "Participants must be off zinc therapy for a minimum of 21 days prior to Day 1 to prevent confounding of study results, as zinc works through upregulation of metallothionein in enterocytes resulting in elevated fecal copper excretion."
      },
      {
        "id": "cond_9",
        "name": "Eligibility – Chelator Washout",
        "instanceType": "Condition",
        "description": "Required discontinuation of chelator therapy before ALXN1840 initiation for baseline copper assessment",
        "text": "To assess the copper baseline during the Inpatient Run-in Period, participants will be discontinued from their chelator therapy for approximately 4 days prior to initiating ALXN1840 while being maintained on a copper-controlled diet."
      },
      {
        "id": "cond_10",
        "name": "Eligibility – Prior ALXN1840 or Tetrathiomolybdate Exposure",
        "instanceType": "Condition",
        "description": "Exclusion based on prior ALXN1840 or tetrathiomolybdate within 1 year",
        "text": "Previous treatment with ALXN1840 or other form of tetrathiomolybdate within 1 year prior to dosing is exclusionary."
      },
      {
        "id": "cond_11",
        "name": "Eligibility – Prior Experimental Therapy Washout",
        "instanceType": "Condition",
        "description": "Avoid carryover from other investigational therapies",
        "text": "Use of an experimental or unapproved/unlicensed therapy at the same time or within 90 days or 5 half-lives, whichever is longer, prior to the Screening Visit is exclusionary."
      },
      {
        "id": "cond_12",
        "name": "Eligibility – Concomitant Medication Washout",
        "instanceType": "Condition",
        "description": "Abstain from prescription and nonprescription medications prior to study",
        "text": "Participants must abstain from taking prescription medications within 14 days or 5 half-lives (whichever is longer) of Day -7 or nonprescription drugs, vitamins, and dietary or herbal supplements within 7 days or 5 half-lives (whichever is longer) before Day -7 and until completion of the follow-up visit, except specific allowed medications."
      },
      {
        "id": "cond_13",
        "name": "Eligibility – Pregnancy Testing and Status",
        "instanceType": "Condition",
        "description": "Requirement for negative pregnancy status and ongoing testing",
        "text": "Women of childbearing potential should only be enrolled after a negative serum pregnancy test result at Screening. Additional urine pregnancy testing will be standard at protocol-defined visits, and females of childbearing potential must perform urine pregnancy tests at least every 4 weeks at their home or the study site throughout their time in the study."
      },
      {
        "id": "cond_14",
        "name": "Eligibility – Ability to Tolerate Controlled Diet",
        "instanceType": "Condition",
        "description": "Requirement to complete and tolerate controlled copper/molybdenum diet",
        "text": "Participants unwilling to consistently complete every meal and tolerate a controlled, limited menu for the duration of the study are excluded. Participants will remain on a copper/molybdenum-controlled diet throughout inpatient Period 1 and 2 and are strongly encouraged to complete all meals."
      },
      {
        "id": "cond_15",
        "name": "Discontinuation of Study Intervention – Triggering Conditions",
        "instanceType": "Condition",
        "description": "Conditions mandating consideration of permanent discontinuation of ALXN1840",
        "text": "Participants must be considered for discontinuation from study intervention if any of the following occur: serious hypersensitivity reaction; severe uncontrolled infection; use of disallowed medication; pregnancy or planned pregnancy; or if Alexion or the Investigator deems it necessary."
      },
      {
        "id": "cond_16",
        "name": "Discontinuation for Abnormal Liver Function",
        "instanceType": "Condition",
        "description": "Link to dose modification criteria for liver-related discontinuation decisions",
        "text": "Discontinuation of study intervention for abnormal liver function should be considered when a participant meets one of the conditions outlined in the Dose Modification criteria or if the Investigator believes that it is in the best interest of the participant."
      },
      {
        "id": "cond_17",
        "name": "Clinically Significant ECG Findings Post-enrollment",
        "instanceType": "Condition",
        "description": "Decision on continued participation based on ECG abnormalities",
        "text": "If a clinically significant finding is identified on ECG (including changes from baseline in QTcF) after enrollment, the Investigator or qualified designee will determine if the participant can continue in the study and if any change in participant management is needed."
      },
      {
        "id": "cond_18",
        "name": "Adaptive Design Features",
        "instanceType": "Condition",
        "description": "Investigator discretion for adaptive features within defined limits without protocol amendment",
        "text": "This study incorporates the use of an adaptive design. Adaptive features may be implemented at the discretion of the Investigator to support conduct of the study and do not require amendment of the protocol; adaptive features and their limits are described in Table 4."
      },
      {
        "id": "cond_19",
        "name": "Lost to Follow-up Determination",
        "instanceType": "Condition",
        "description": "Conditions under which a participant is considered lost to follow-up",
        "text": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site despite at least 3 telephone calls and, if necessary, a certified letter to the last known mailing address, with all attempts documented."
      },
      {
        "id": "cond_20",
        "name": "Maximum Number of Dose Rechallenges",
        "instanceType": "Condition",
        "description": "Limit on rechallenge attempts after safety-related interruption",
        "text": "A maximum of 3 rechallenges will be allowed for participants in whom ALXN1840 was interrupted per dose modification criteria."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screening/Run-in to Treatment Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_run_in",
        "toElementId": "epoch_treatment_15mg",
        "text": "Participants eligible for the study will be enrolled on Day -7 and initiated on a copper- and molybdenum-controlled diet, then admitted to the CRU for Treatment Period 1 on Day -8 and start ALXN1840 at 15 mg/day on Day 1 following discontinuation of chelator therapy for approximately 4 days and zinc therapy for at least 21 days."
      },
      {
        "id": "trans_2",
        "name": "Dose Escalation from 15 mg/day to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Participants will be administered ALXN1840 at a dose of 15 mg/day on Day 1 through Day 28 and then increase to 30 mg/day on Day 29 after the Safety Review Committee reviews available safety data through Day 23. If safety concerns exist, participants may remain on 15 mg/day for the duration of the study."
      },
      {
        "id": "trans_3",
        "name": "Dose Reduction or Interruption Based on Safety Criteria",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_any",
        "toElementId": "dose_reduced_or_interrupted",
        "text": "The dose should be decreased or interrupted if any of the relevant Dose Modification Criteria in Table 7 are met, such as hematological abnormalities, liver test abnormalities, neurologic or psychiatric worsening. Deviation from these guidelines must be agreed with the Alexion Medical Monitor."
      },
      {
        "id": "trans_4",
        "name": "Temporary Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_any",
        "toElementId": "dose_interrupted",
        "text": "If bilirubin > 2 × ULN accompanied by ALT > 3 × ULN indicative of liver injury occurs, ALXN1840 dosing should be temporarily interrupted, with weekly repeat testing; rechallenge, if considered, is at 15 mg every other day or less frequent when bilirubin is below ULN and requires approval of the Alexion Medical Monitor."
      },
      {
        "id": "trans_5",
        "name": "Dose Rechallenge After Safety Event",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_interrupted",
        "toElementId": "dose_rechallenged",
        "text": "Following resolution of safety abnormalities triggering dose interruption, participants may be rechallenged, typically at 15 mg every other day, up to a maximum of 3 rechallenges; dose and frequency may be changed by the Investigator in consultation with the Medical Monitor."
      },
      {
        "id": "trans_6",
        "name": "Discontinuation of Study Intervention for Safety",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "dose_any",
        "toElementId": "intervention_discontinued",
        "text": "Participants must be considered for discontinuation from study intervention if serious hypersensitivity reaction, severe uncontrolled infection, use of disallowed medication, pregnancy or planned pregnancy occurs, or if Alexion or the Investigator deems discontinuation is necessary."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation of Study Intervention for Abnormal Liver Function",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "dose_any",
        "toElementId": "intervention_discontinued",
        "text": "Discontinuation of study intervention for abnormal liver function should be considered when liver-related dose modification criteria are met or when the Investigator believes it is in the best interest of the participant."
      },
      {
        "id": "trans_8",
        "name": "Participant Withdrawal from Study",
        "instanceType": "TransitionRule",
        "transitionType": "Early Termination",
        "fromElementId": "epoch_any",
        "toElementId": "study_early_termination",
        "text": "A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons; an early discontinuation visit should be conducted if possible and the participant is permanently discontinued from both study intervention and study participation."
      },
      {
        "id": "trans_9",
        "name": "Lost to Follow-up Leading to Withdrawal",
        "instanceType": "TransitionRule",
        "transitionType": "Early Termination",
        "fromElementId": "epoch_any",
        "toElementId": "study_early_termination",
        "text": "If a participant repeatedly fails to return for scheduled visits and remains unreachable despite at least 3 telephone calls and, if necessary, a certified letter, he/she will be considered to have withdrawn from the study and will be permanently discontinued."
      },
      {
        "id": "trans_10",
        "name": "Transition to Post-study Therapy",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment_completion",
        "toElementId": "epoch_post_study_care",
        "text": "Following completion of both inpatient periods (Day 40), participants will either transition to therapy that was discontinued before enrollment, transition to other standard of care therapy as directed by the treating physician, or, at the discretion of the treating physician, consider continuation of ALXN1840 treatment under preapproval access."
      },
      {
        "id": "trans_11",
        "name": "Study-site Closure or Study Termination",
        "instanceType": "TransitionRule",
        "transitionType": "Early Termination",
        "fromElementId": "site_active",
        "toElementId": "site_closed",
        "text": "Alexion may close a study site or terminate the study at any time for reasons including but not limited to Investigator non-compliance, inadequate recruitment, or discontinuation of further study intervention development; the Investigator may also initiate site closure given reasonable cause and sufficient notice."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion for Participant",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he or she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities, typically the End of Study Visit on Day 54 (±2 days)."
      },
      {
        "id": "exit_2",
        "name": "Early Termination – Participant Withdrawal or Investigator Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Early termination occurs when a participant withdraws consent at any time or is withdrawn at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons; an early discontinuation visit should be performed per the SoA."
      },
      {
        "id": "exit_3",
        "name": "Early Termination – Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "If a participant repeatedly fails to return for scheduled visits and cannot be contacted despite documented attempts (at least 3 telephone calls and, if necessary, a certified letter), the participant is considered to have withdrawn from the study and is permanently discontinued."
      },
      {
        "id": "exit_4",
        "name": "Discontinuation of Study Intervention Only",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "In rare instances, the study intervention may be permanently discontinued for a participant while the participant remains in the study for safety follow-up; this occurs in the setting of serious hypersensitivity, severe uncontrolled infection, pregnancy, use of disallowed medication, or other safety reasons per Investigator or Sponsor judgment."
      },
      {
        "id": "exit_5",
        "name": "Site-level Early Closure",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A study site may be closed before planned completion due to Investigator non-compliance with protocol or GCP, inadequate recruitment, or discontinuation of further study intervention development; all participants at the site must complete early discontinuation or end-of-study visits as applicable."
      },
      {
        "id": "exit_6",
        "name": "Study-level Early Termination",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to terminate the study at any time; in such cases all Investigators, ethics committees, regulatory authorities, and participants are informed, and appropriate participant therapy and/or follow-up is assured."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Escalation Decision at Approximately Week 4",
        "timepointId": "pt_day29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At around Day 29, decision to titrate from 15 mg/day to 30 mg/day based on Safety Review Committee assessment of safety data through Day 23 and Investigator/Alexion evaluation of participant risk; if safety concerns are present, participant may remain on 15 mg/day.",
        "conditionIds": [
          "cond_1",
          "cond_2"
        ]
      },
      {
        "id": "dec_2",
        "name": "Dose Modification Decision per Dose Modification Criteria",
        "timepointId": "pt_any_visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At any point during treatment when dose modification criteria are met (hematologic, hepatic, neurologic, or psychiatric), the Investigator and Medical Monitor decide on dose reduction, interruption, or rechallenge, respecting the maximum allowed number of rechallenges.",
        "conditionIds": [
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_20"
        ]
      },
      {
        "id": "dec_3",
        "name": "Study Intervention Discontinuation Decision",
        "timepointId": "pt_any_time",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to permanently discontinue ALXN1840 based on occurrence of serious hypersensitivity, severe uncontrolled infection, pregnancy, use of disallowed medication, abnormal liver function meeting criteria, or clinically significant ECG or other safety findings.",
        "conditionIds": [
          "cond_15",
          "cond_16",
          "cond_17"
        ]
      },
      {
        "id": "dec_4",
        "name": "Lost to Follow-up Determination",
        "timepointId": "pt_missed_visits",
        "instanceType": "ScheduledDecisionInstance",
        "description": "After repeated missed visits and documented unsuccessful contact attempts, the Investigator decides to classify the participant as lost to follow-up and withdraw them from the study.",
        "conditionIds": [
          "cond_19"
        ]
      },
      {
        "id": "dec_5",
        "name": "Post-study Therapy Transition Decision",
        "timepointId": "pt_day40_to_eos",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Following completion of Day 40, the treating physician decides whether the participant will transition back to pre-study therapy, to other standard-of-care therapy, or request continuation of ALXN1840 under preapproval access."
      }
    ],
    "summary": {
      "timingCount": 43,
      "conditionCount": 20,
      "transitionRuleCount": 11,
      "exitCount": 6
    }
  }
}